Clinical Trial Update: Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Fruquintinib to Bevacizumab plus chemotherapy as second-line therapy for RAS-mutant metastatic colorectal cancer is not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Chemotherapy (chemotherapy)
• Fruquintinib (fruquintinib)

Snippet

Sponsor: Fudan University | Conditions: Colorectal Cancer | Phase 3 | Status: NOT_YET_RECRUITING